Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

Summary

This is a single-center, prospective, single arm phase II study to evaluate the efficacy and safety of nab-paclitaxel plus carboplatin (with trastuzumab for HER-2 positive patients) as neoadjuvant therapy in operable locally advanced breast cancer patients. The primary objective is pCR. The secondary objectives include ORR, 3-yr DFS, OS and safety. The sample size is 30.

Timeline

Start

2012-06

Primary completion

2013-09

Completion

2017-06

Drugs

Indications